Can HIPEC be used against platinum-resistance and for inducing sensitivity to PARP inhibitors in ovarian cancer?

Hyperthermic intraperitoneal chemotherapy (HIPEC) has emerged as a main comprehensive treatment of epithelial ovarian cancer (EOC). Despite much criticism to this approach, HIPEC has shown cost-effective benefits in both progression-free survival and overall survival for high tumor burden with no im...

Descripción completa

Detalles Bibliográficos
Autores principales: Batista, Thales Paulo, Dal Molin, Graziela Zibetti
Formato: Online Artículo Texto
Lenguaje:English
Publicado: OAE Publishing Inc. 2020
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8992489/
https://www.ncbi.nlm.nih.gov/pubmed/35582446
http://dx.doi.org/10.20517/cdr.2020.27

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8992489/
https://www.ncbi.nlm.nih.gov/pubmed/35582446
http://dx.doi.org/10.20517/cdr.2020.27

Ejemplares similares